Mozavaptan

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

Mozavaptan

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
CAS Number	137975-06-5 Y
PubChem CID	119369
IUPHAR/BPS	2197
ChemSpider	106618 Y
UNII	17OJ42922Y
ChEMBL	ChEMBL420762 Y
CompTox Dashboard (EPA)	DTXSID8057641
Chemical and physical data
Formula	C27H29N3O2
Molar mass	427.548 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) Y Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

References

• Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
• "Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from the original on 2012-02-13.